LXRX stock forecast
Our latest prediction for Lexicon Pharmaceuticals, Inc.'s stock price was made on the Sept. 18, 2019 when the stock price was at 3.80$.
In the short term (2weeks), LXRX's stock price should outperform the market by 7.07%. During that period the price should oscillate between -12.12% and +41.97%.
In the medium term (3months), LXRX's stock price should outperform the market by 11.00%. During that period the price should oscillate between -22.86% and +103.93%.Get email alerts
About Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. It drug candidates include XERMELO, Sotagliflozin, LX2761, and LX9211. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.
At the moment the company generates 43M USD in revenues.
On its last earning announcement, the company reported a loss of -0.84$ per share.
The book value per share is -0.05$
Three months stock forecastSept. 18, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|